Rhinovirus Infection - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rhinovirus Infection - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Rhinovirus Infection - Pipeline Review, H1 2015', provides an overview of the Rhinovirus Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhinovirus Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rhinovirus Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rhinovirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rhinovirus Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rhinovirus Infection Overview 7
Therapeutics Development 8
Pipeline Products for Rhinovirus Infection - Overview 8
Pipeline Products for Rhinovirus Infection - Comparative Analysis 9
Rhinovirus Infection - Therapeutics under Development by Companies 10
Rhinovirus Infection - Therapeutics under Investigation by Universities/Institutes 12
Rhinovirus Infection - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Rhinovirus Infection - Products under Development by Companies 15
Rhinovirus Infection - Products under Investigation by Universities/Institutes 16
Rhinovirus Infection - Companies Involved in Therapeutics Development 17
AIMM Therapeutics B.V. 17
Biological Mimetics, Inc. 18
Biota Pharmaceuticals, Inc. 19
Boehringer Ingelheim GmbH 20
Johnson & Johnson 21
Myelo Therapeutics GmbH 22
Theraclone Sciences, Inc. 23
Rhinovirus Infection - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
KR-22809 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Myelo-001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
OBR-5340 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PL-402 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Recombinant Protein for Rhinovirus Infection - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rhinovirus [serotype 39] vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule for Rhinovirus Infection - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Rhinovirus Infection - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules for Rhinovirus Infections - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit RNA Polymerase for Rhinovirus and Picornaviridae Infections - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
vapendavir - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Rhinovirus Infection - Recent Pipeline Updates 48
Rhinovirus Infection - Dormant Projects 50
Rhinovirus Infection - Product Development Milestones 51
Featured News & Press Releases 51
Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables
Number of Products under Development for Rhinovirus Infection, H1 2015 8
Number of Products under Development for Rhinovirus Infection - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Rhinovirus Infection - Pipeline by AIMM Therapeutics B.V., H1 2015 17
Rhinovirus Infection - Pipeline by Biological Mimetics, Inc., H1 2015 18
Rhinovirus Infection - Pipeline by Biota Pharmaceuticals, Inc., H1 2015 19
Rhinovirus Infection - Pipeline by Boehringer Ingelheim GmbH, H1 2015 20
Rhinovirus Infection - Pipeline by Johnson & Johnson, H1 2015 21
Rhinovirus Infection - Pipeline by Myelo Therapeutics GmbH, H1 2015 22
Rhinovirus Infection - Pipeline by Theraclone Sciences, Inc., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Rhinovirus Infection Therapeutics - Recent Pipeline Updates, H1 2015 48
Rhinovirus Infection - Dormant Projects, H1 2015 50